Work

Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.6070

Authors: Panayiotis Savvides, Sabarish Ayyappan, Min Yao, Rod Rezaee, Chad Zender, Jay Wasman, Pingfu Fu, Mitchell Machtay, Pierre Lavertu, Michael K. Gibson

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2529027804

Cites:

Cited by: 3

Related to: 10